spironolactone has been researched along with endothelin-1 in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Lüscher, TF; Quaschning, T; Ruschitzka, F; Shaw, S | 1 |
| Cavallin, M; Nussdorfer, GG; Pessina, AC; Rossi, GP | 1 |
| Chen, X; He, G; Schiffrin, EL; Tostes, RC; Touyz, RM | 1 |
| Ahn, S; Duprez, D; Galanti, L; Gurné, O; Ketelslegers, JM; Robert, A; Rousseau, MF; Van Mieghem, W | 1 |
| Hara, Y; Imaki, T; Naruse, M; Takagi, S; Takano, K; Tanabe, A | 1 |
| Backs, J; Buss, SJ; Haass, M; Hardt, SE; Katus, HA; Kreusser, MM; Maser-Gluth, C | 1 |
| Ge, Y; Huang, Y; Kohan, DE | 1 |
| Kara-Perz, H; Kosicka, T; Perz, S | 1 |
| Simoni, J; Wesson, DE | 1 |
| Ferrari, M; Figulla, HR; Goebel, B; Jung, C; Kiehntopf, M; Lauten, A; Rademacher, W; Schumm, J; Uth, O | 1 |
| Cain, BD; Gumz, ML; Stow, LR; Voren, GE; Wingo, CS | 1 |
| Hermsen, D; Scherbaum, WA; Schinner, S; Schott, M; Vogt, S; Willenberg, HS; Winkler, E | 1 |
| Chan, SY; Handy, DE; Leopold, JA; Loscalzo, J; Mahoney, CE; Maron, BA; White, K; Zhang, YY | 1 |
| Chen, L; Liu, K; Peng, W; Pouranan, V; Tang, R; Wu, H; Xiang, A; Xiao, Z; Yuan, M; Zhang, W; Zhou, Q | 1 |
| Bagrov, AY; Bagrov, KA; Emelianov, IV; Fedorova, OV; Frolova, EV; Grigorova, YN; Juhasz, O; Konradi, AO; Lakatta, EG; Marshall, CA; Wei, W | 1 |
| Bramlage, P; Fay, R; Girerd, N; Ketelslegers, JM; Michel, JB; Olivier, A; Pitt, B; Rossignol, P; Vincent, J; Zannad, F | 1 |
| Aljohmani, AI; Alzoubi, KH; Mayyas, FA | 1 |
3 trial(s) available for spironolactone and endothelin-1
| Article | Year |
|---|---|
Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.
Topics: Aged; Aged, 80 and over; Angiotensin II; Atrial Natriuretic Factor; Endothelin-1; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Spironolactone; Treatment Outcome | 2002 |
[Does spironolactone use at arterial hypertension therapy protect endothelium also in smoking patients?].
Topics: Aldosterone; Diuretics; Endothelin-1; Endothelium, Vascular; Female; Humans; Hypertension; Male; Middle Aged; Renin; Smoking; Spironolactone | 2009 |
Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Ac
Topics: Aged; Biomarkers; Endothelin-1; Eplerenone; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Natriuretic Peptide, Brain; Predictive Value of Tests; Spironolactone; Survival Rate; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left | 2017 |
14 other study(ies) available for spironolactone and endothelin-1
| Article | Year |
|---|---|
Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Animals; Aorta; Blood Pressure; Body Weight; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Eplerenone; Glycyrrhiza; Glycyrrhizic Acid; Heart Rate; Hydroxysteroid Dehydrogenases; Hypertension; In Vitro Techniques; Male; Mineralocorticoid Receptor Antagonists; Molecular Structure; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Plants, Medicinal; Rats; Rats, Inbred WKY; Spironolactone; Vasodilation | 2001 |
The endothelin-aldosterone axis and cardiovascular diseases.
Topics: Adrenal Cortex; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Collagen; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Morbidity; Randomized Controlled Trials as Topic; Receptor, Endothelin A; Receptor, Endothelin B; Renin-Angiotensin System; Spironolactone | 2001 |
Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension.
Topics: Aldosterone; Analysis of Variance; Animals; Dansyl Compounds; DNA; Electrophoretic Mobility Shift Assay; Endothelin Receptor Antagonists; Endothelin-1; Hypertension; Immunohistochemistry; Kidney; Macrophages; Male; Mineralocorticoid Receptor Antagonists; NF-kappa B; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Spironolactone; Transcription Factor AP-1 | 2002 |
Effects of AT1 receptor antagonist and spironolactone on cardiac expression of ET-1 mRNA in SHR-SP/Izm.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Disease Models, Animal; Drug Therapy, Combination; Endothelin-1; Gene Expression Regulation; Hypertension; Injections, Subcutaneous; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Rats; Rats, Inbred SHR; Rats, Inbred WKY; RNA, Messenger; Spironolactone; Tetrazoles; Time Factors | 2004 |
Spironolactone preserves cardiac norepinephrine reuptake in salt-sensitive Dahl rats.
Topics: Aldosterone; Animals; Body Weight; Echocardiography; Endothelin-1; Heart; Heart Ventricles; Hemodynamics; Male; Mineralocorticoid Receptor Antagonists; Models, Statistical; Myocardium; Neurons; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Organ Size; Perfusion; Rats; Rats, Inbred Dahl; Rats, Wistar; Salts; Sodium Chloride; Spironolactone | 2006 |
Role of the renin-angiotensin-aldosterone system in collecting duct-derived endothelin-1 regulation of blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Blood Pressure; DNA Primers; Endothelin-1; Female; Hypertension; Kidney Tubules, Collecting; Male; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan | 2008 |
Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali diet.
Topics: Acid-Base Equilibrium; Acidosis; Administration, Oral; Aldosterone; Animals; Bicarbonates; Calcium Gluconate; Dietary Supplements; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Eplerenone; Female; Glomerular Filtration Rate; Kidney; Male; Microdialysis; Mineralocorticoid Receptor Antagonists; Nephrectomy; Phenylpropionates; Pyrimidines; Rats; Rats, Wistar; Receptor, Endothelin A; Renal Insufficiency; Spironolactone; Time Factors | 2010 |
Microvascular tissue perfusion is impaired in acutely decompensated heart failure and improves following standard treatment.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Disease Progression; Endothelin-1; Female; Heart Failure; Hemodynamics; Humans; Male; Microcirculation; Myocardial Perfusion Imaging; Natriuretic Peptide, Brain; Norepinephrine; Prognosis; Regional Blood Flow; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone; Statistics, Nonparametric; Stroke Volume; Ventricular Function, Left | 2011 |
Dexamethasone stimulates endothelin-1 gene expression in renal collecting duct cells.
Topics: Animals; Blotting, Western; Cell Line; Dexamethasone; Dose-Response Relationship, Drug; Endothelin-1; Gene Expression; Glucocorticoids; Hormone Antagonists; Kidney Tubules, Collecting; Mifepristone; Mineralocorticoid Receptor Antagonists; Mutation; Promoter Regions, Genetic; Protein Binding; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; Spironolactone | 2012 |
Endothelin-1 and adrenomedullin plasma levels after exposure to fludrocortisone, dexamethasone, and spironolactone.
Topics: Adrenal Insufficiency; Adrenomedullin; Adult; Anti-Inflammatory Agents; Biomarkers; Dexamethasone; Diuretics; Endothelin-1; Female; Fludrocortisone; Humans; Hyperaldosteronism; Hypertension; Male; Middle Aged; Renin-Angiotensin System; Spironolactone | 2012 |
Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.
Topics: Aldosterone; Animals; Cells, Cultured; Cysteine; Disease Models, Animal; Endothelial Cells; Endothelin-1; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Male; Mineralocorticoid Receptor Antagonists; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidation-Reduction; Oxidative Stress; Pulmonary Artery; Pulmonary Wedge Pressure; Rats; Rats, Sprague-Dawley; Receptor, Endothelin B; Spironolactone; Sulfhydryl Compounds | 2012 |
Spironolactone rescues Dot1a-Af9-mediated repression of endothelin-1 and improves kidney injury in streptozotocin-induced diabetic rats.
Topics: Acute Kidney Injury; Aldosterone; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Endothelin-1; Histone-Lysine N-Methyltransferase; Humans; Methyltransferases; Mice; Nuclear Proteins; Promoter Regions, Genetic; Rats; Spironolactone; Streptozocin; Up-Regulation | 2012 |
Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists.
Topics: Animals; Aorta; Arterial Pressure; Bufanolides; Canrenone; Cells, Cultured; Collagen Type I; Endothelin-1; Erythrocytes; Female; Fibrosis; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nitroprusside; Pulse Wave Analysis; Rats; Rats, Wistar; Sodium-Potassium-Exchanging ATPase; Spironolactone; Vasodilator Agents | 2015 |
The Impact of Spironolactone on Markers of Myocardial Oxidative Status, Inflammation and Remodeling in Hyperthyroid Rats.
Topics: Aldosterone; Animals; Antioxidants; Biomarkers; Blood Pressure; Body Weight; Cardiovascular Diseases; Endothelin-1; Heart; Heart Rate; Hyperthyroidism; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Nitrites; Organ Size; Oxidative Stress; Random Allocation; Rats; Spironolactone; Thyroid Hormones; Thyroxine; Transforming Growth Factor beta | 2020 |